IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

por Metz, Richard, Rust, Sonja, DuHadaway, James B., Mautino, Mario R., Munn, David H., Vahanian, Nicholas N., Link, Charles J., Prendergast, George C.
Publicado 2012

Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responses

por Chen, Wenlan Alex, Zhang, Jinjin, Hall, Katie M., Martin, Carol B., Kisselev, Serguei, Dasen, Emily J., Vahanian, Nicholas N., Link, Charles J., Martin, Brian K.
Publicado 2017

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

por Soliman, Hatem H., Jackson, Erica, Neuger, Tony, Dees, E. Claire, Harvey, R. Donald, Han, Hyo, Ismail-Khan, Roohi, Minton, Susan, Vahanian, Nicholas N., Link, Charles, Sullivan, Daniel M., Antonia, Scott
Publicado 2014

Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1

por Brincks, Erik L., Adams, James, Wang, Lifu, Turner, Benjamin, Marcinowicz, Agnieszka, Ke, Jiyuan, Essmann, Michael, Mautino, Lucía M., Allen, Clarissa Van, Kumar, Sanjeev, Vahanian, Nicholas, Link, Charles, Mautino, Mario R.
Publicado 2020

A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge

por Mandell, Robert B., Koukuntla, Ramesh, Mogler, Laura J.K., Carzoli, Andrea K., Freiberg, Alexander N., Holbrook, Michael R., Martin, Brian K., Staplin, William R., Vahanian, Nicholas N., Link, Charles J., Flick, Ramon
Publicado 2010

A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors

por Nayak, Asha, Hao, Zhonglin, Sadek, Ramses, Vahanian, Nicholas, Ramsey, W Jay, Kennedy, Eugene, Mautino, Mario, Link, Charles, Bourbo, Pamela, Dobbins, Robin, Adams, Kelly, Diamond, Allison, Marshall, Lisa, Munn, David H, Janik, John, Khleif, Samir N
Publicado 2014

A phase I study of indoximod in patients with advanced malignancies

por Soliman, Hatem H., Minton, Susan E., Han, Hyo Sook, Ismail-Khan, Roohi, Neuger, Anthony, Khambati, Fatema, Noyes, David, Lush, Richard, Chiappori, Alberto A., Roberts, John D., Link, Charles, Vahanian, Nicholas N., Mautino, Mario, Streicher, Howard, Sullivan, Daniel M., Antonia, Scott J.
Publicado 2016

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

por Nayak-Kapoor, Asha, Hao, Zhonglin, Sadek, Ramses, Dobbins, Robin, Marshall, Lisa, Vahanian, Nicholas N., Jay Ramsey, W., Kennedy, Eugene, Mautino, Mario R., Link, Charles J., Lin, Ray S., Royer-Joo, Stephanie, Liang, Xiaorong, Salphati, Laurent, Morrissey, Kari M., Mahrus, Sami, McCall, Bruce, Pirzkall, Andrea, Munn, David H., Janik, John E., Khleif, Samir N.
Publicado 2018

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

por Zakharia, Yousef, McWilliams, Robert R, Rixe, Olivier, Drabick, Joseph, Shaheen, Montaser F, Grossmann, Kenneth F, Kolhe, Ravindra, Pacholczyk, Rafal, Sadek, Ramses, Tennant, Lucinda L, Smith, Christopher M, Kennedy, Eugene P, Link Jr, Charles J, Vahanian, Nicholas N, Yu, Jiayi, Shen, Steven S, Brincks, Erik L, Rossi, Gabriela R, Munn, David, Milhem, Mohammed
Publicado 2021